Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2023) 142 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2023-181813

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Blood (2022) 140 (Supplement 1): 7272–7274.

https://doi.org/10.1182/blood-2022-163483

Published: 2022

Journal Articles

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Fabio Serpenti, Anushka Shankar, Nicolo' Rampi, Cristina Mocellin, Cecilia Fidanza, Maria Cecilia Goldaniga, Giorgia Saporiti, Matteo Claudio Da Via, Giulia Galassi, Loredana Pettine, Filippo Bagnoli, Niccolo Bolli, Luca Baldini, Alessandra Pompa, Francesco Onida

Blood (2022) 140 (Supplement 1): 12576–12577.

https://doi.org/10.1182/blood-2022-169454

Published: 2022

Journal Articles

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Blood (2022) 140 (Supplement 1): 3638–3641.

https://doi.org/10.1182/blood-2022-165977

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Francesca Cavallaro, Francesco Versino, Fabio Serpenti, Simona Iacobelli, Silvia Alberti Violetti, Giorgia Saporiti, Maria Goldaniga, Giulia Galassi, Filippo Bagnoli, Nicolo' Rampi, Kordelia Barbullushi, Alessandro Bosi, Giulio Cassanello, Gabriele Simontacchi, Concetta Schiavone, Luca Baldini, Emilio Berti, Francesco Onida

Blood (2022) 140 (Supplement 1): 7721–7722.

https://doi.org/10.1182/blood-2022-169660

Published: 2022

Journal Articles

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Blood (2021) 138 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2021-146907

Published: 2021

Journal Articles

MGUS and Chip: Two Faces, but Not of the Same Medal

Matteo Claudio Da Via, Marta Lionetti, Antonio Matera, Erica Travaglino, Ugo Lucca, Emma Riva, Mauro Tettamanti, Luca Baldini, Antonino Neri, Matteo G. Della Porta, Niccolo Bolli

Blood (2021) 138 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2021-147890

Published: 2021

Journal Articles

Dissection of Bone Marrow Microenvironment By Single Cell RNA Sequencing in Warm AIHA Patients: A Proof-of-Concept Analysis

Bruno Fattizzo, Matteo Claudio Da Via', Juri Alessandro Giannotta, Paola Bianchi, Luca Baldini, Niccolo Bolli, Wilma Barcellini

Blood (2021) 138 (Supplement 1): 931.

https://doi.org/10.1182/blood-2021-149546

Published: 2021

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Emmanuel Gyan, Maria Chiara Tisi, Francesco Merli, Luca Baldini, Francesco Di Raimondo, Santiago Mercadal, Benedetta Puccini, Elisabeth Vandenberghe, Ka Lung Wu, Anthony Boland, Rikisha Shah Gupta, Anna van Troostenburg, Carolyn Dunnill, Heribert Ramroth, Nishanthan Rajakumaraswamy, Gilles Salles

Blood (2021) 138 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2021-146066

Published: 2021

Journal Articles

Simoultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience

Anna Ines Gregorini, MD, Francesca Gaia Rossi, MD, Sara Lodi Rizzini, MD, Valeria Ferla, MD, Giorgia Saporiti, MD, Loredana Pettine, MD, Mariarita Sciumè, MD, Fabio Serpenti, MD, Veronica Mattiello, Maria Chiara Barbanti, MD, Giorgio Maggioni, Luca Baldini, MD PhD, Roberto Scarani, MD, Massimo Pizzuto, MD, Francesco Onida, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142631

Published: 2020

Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135874

Published: 2020

Journal Articles

Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

Matteo Claudio Da Via', MD, Bachisio Ziccheddu, Matteo Dugo, Marta Lionetti, PhD, Katia Todoerti, PhD, Mattia D'Agostino, MD, Antonino Neri, MD, Luca Baldini, MD PhD, Paolo Corradini, Francesco Maura, MD, Niccolo Bolli, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-136211

Published: 2020

Journal Articles

Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience

Viviana Beatrice Valli, MD, Filippo Grillo Ruggieri, MD, Giorgia Saporiti, MD, Silvia Alberti Violetti, MD, Concetta Schiavone, MD, Federica Irene Grifoni, MD, Maria Cecilia Goldaniga, MD, Francesca Casarin, Valeria Ferla, MD, Luca Baldini, MD PhD, Emilio Berti, MD, Francesco Onida, MD

Blood (2019) 134 (Supplement_1): 2042.

https://doi.org/10.1182/blood-2019-131144

Published: 2019

Journal Articles

Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center

Francesco Onida, MD, Giorgia Saporiti, MD, Viviana Beatrice Valli, MD, Silvia Alberti Violetti, MD, Federica Irene Grifoni, MD, Maria Cecilia Goldaniga, MD, Mariarita Sciumè, MD, Luca Baldini, MD PhD, Emilio Berti, MD

Blood (2019) 134 (Supplement_1): 5744.

https://doi.org/10.1182/blood-2019-131501

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes

Blood (2018) 132 (Supplement 1): 125.

https://doi.org/10.1182/blood-2018-99-116716

Published: 2018

Journal Articles

Plasma Cell Disease Genotyping with the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 327.

https://doi.org/10.1182/blood.V130.Suppl_1.327.327

Published: 2017

Journal Articles

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Vittorio Montefusco, MD, Alessandro Corso, MD, Monica Galli, MD PhD, Elena Tagliabue, Sara Pezzatti, Francesca Patriarca, MD, Filippo Gherlinzoni, MD, Renato Zambello, MD, Simona Sammassimo, Magda Marcatti, MD, Andrea Nozza, Claudia Crippa, MD, Anna Maria Cafro, MD, Luca Baldini, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 836.

https://doi.org/10.1182/blood.V130.Suppl_1.836.836

Published: 2017

NARROW

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

MGUS and Chip: Two Faces, but Not of the Same Medal

Dissection of Bone Marrow Microenvironment By Single Cell RNA Sequencing in Warm AIHA Patients: A Proof-of-Concept Analysis

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Simoultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience

Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes

Plasma Cell Disease Genotyping with the Liquid Biopsy

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only